Bioverativ (Nasdaq: BIVV) to Ring The Nasdaq Stock Market Opening Bell
February 14 2017 - 10:00AM
What: Bioverativ (Nasdaq:BIVV), a newly
independent, global biotechnology company focused on the discovery,
development and commercialization of innovative therapies for
hemophilia and other rare blood disorders, will visit the Nasdaq
MarketSite in Times Square.
In honor of the occasion, John Cox, Chief Executive
Officer, will ring the Opening Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd
& Broadway – Broadcast Studio
When:Wednesday, February 15, 2017 – 9:15 a.m.
to 9:30 a.m. ET
Bioverativ Media Contact:Tracy Vineis(781)
663-4350media@bioverativ.com
Nasdaq MarketSite:Emily Pan(646)
441-5120emily.pan@nasdaq.com
Feed Information:Fiber Line (Encompass
Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as
exclusive content, photo postings, status updates and video of bell
ceremonies, please visit our Facebook
page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our
Instagram page:http://instagram.com/nasdaq.
For livestream of ceremonies and events, please visit our
YouTube page:http://www.youtube.com/nasdaq/live.
For news tweets, please visit our Twitter
page:http://twitter.com/nasdaq.
For exciting viral content and ceremony photos, please visit our
Tumblr page:http://nasdaq.tumblr.com/.
Webcast: A live stream of the Nasdaq Opening
Bell will be available at: https://new.livestream.com/nasdaq/live
or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://business.nasdaq.com/discover/market-bell-ceremonies and
click on the market open of your choice.
About BioverativBioverativ (NASDAQ:BIVV) is a
global biotechnology company dedicated to transforming the lives of
people with hemophilia and other rare blood disorders through
world-class research, development and commercialization of
innovative therapies. Launched in 2017 following separation from
Biogen Inc., Bioverativ builds upon a strong heritage of scientific
innovation and is committed to actively working with the blood
disorders community. The company’s mission is to create progress
for patients where they need it most and its hemophilia therapies
when launched represented the first major advancements in
hemophilia treatment in more than two decades. For more
information, visit www.bioverativ.com or follow @bioverativ on
Twitter.
About NasdaqNasdaq (Nasdaq:NDAQ) is a leading
provider of trading, clearing, exchange technology, listing,
information and public company services across six continents.
Through its diverse portfolio of solutions, Nasdaq enables clients
to plan, optimize and execute their business vision with
confidence, using proven technologies that provide transparency and
insight for navigating today's global capital markets. As the
creator of the world's first electronic stock market, its
technology powers more than 85 marketplaces in 50 countries, and 1
in 10 of the world's securities transactions. Nasdaq is home to
approximately 3,800 listed companies with a market value of $10.1
trillion and nearly 18,000 corporate clients. To learn more, visit:
business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024
